Company profile WVE
There is not enough data for Wave Life Sciences - Biotechnology to provide analysis
There is not enough data for Wave Life Sciences - Biotechnology to provide correlation calculation
There is not enough data for Wave Life Sciences - Biotechnology to provide analysis
There is not enough data for genetic medicine company to provide analysis
There is not enough data for genetic medicine company to provide correlation calculation
There is not enough data for genetic medicine company to provide analysis
There is not enough data for stereopure oligonucleotides to provide analysis
There is not enough data for stereopure oligonucleotides to provide correlation calculation
There is not enough data for stereopure oligonucleotides to provide analysis
There is not enough data for RNA correction to provide analysis
There is not enough data for RNA correction to provide correlation calculation
There is not enough data for RNA correction to provide analysis
There is not enough data for protein modulation to provide analysis
There is not enough data for protein modulation to provide correlation calculation
There is not enough data for protein modulation to provide analysis
There is not enough data for functional protein production to provide analysis
There is not enough data for functional protein production to provide correlation calculation
There is not enough data for functional protein production to provide analysis
There is not enough data for disease-promoting RNA and protein reduction to provide analysis
There is not enough data for disease-promoting RNA and protein reduction to provide correlation calculation
There is not enough data for disease-promoting RNA and protein reduction to provide analysis
After 39 days of this quarter the interest is at 25.0. Based on that we can calculate that during remaining 52 days it will total up to 58.0. amyotrophic lateral sclerosis treatment expected interest is significantly lower compared to previous quarter (-70.1%) and same quarter last year (-66.7%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 66 | 100 51.5% QoQ | 40 -60.0% QoQ | 177 342.5% QoQ |
| 2020 | 161 143.9% YoY -9.0% QoQ | 91 -9.0% YoY -43.5% QoQ | 55 37.5% YoY -39.6% QoQ | 37 -79.1% YoY -32.7% QoQ |
| 2021 | 115 -28.6% YoY 210.8% QoQ | 43 -52.7% YoY -62.6% QoQ | 120 118.2% YoY 179.1% QoQ | 197 432.4% YoY 64.2% QoQ |
| 2022 | 194 68.7% YoY -1.5% QoQ | 79 83.7% YoY -59.3% QoQ | 60 -50.0% YoY -24.1% QoQ | 128 -35.0% YoY 113.3% QoQ |
| 2023 | 174 -10.3% YoY 35.9% QoQ | 220 178.5% YoY 26.4% QoQ | 128 113.3% YoY -41.8% QoQ | 194 51.6% YoY 51.6% QoQ |
| 2024 | 25 -85.6% YoY -87.1% QoQ | - | - | - |
The average 5 years interest of amyotrophic lateral sclerosis treatment was 9.21 per week. The last year interest of amyotrophic lateral sclerosis treatment compared to the last 5 years has changed by 47.99%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 58.49%.
After 39 days of this quarter the interest is at 47.0. Based on that we can calculate that during remaining 52 days it will total up to 110.0. frontotemporal dementia treatment expected interest is significantly lower compared to previous quarter (-76.1%) and same quarter last year (-63.6%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 152 | 78 -48.7% QoQ | 114 46.2% QoQ | 142 24.6% QoQ |
| 2020 | 226 48.7% YoY 59.2% QoQ | 41 -47.4% YoY -81.9% QoQ | 110 -3.5% YoY 168.3% QoQ | 20 -85.9% YoY -81.8% QoQ |
| 2021 | 98 -56.6% YoY 390.0% QoQ | 109 165.9% YoY 11.2% QoQ | 121 10.0% YoY 11.0% QoQ | 125 525.0% YoY 3.3% QoQ |
| 2022 | 221 125.5% YoY 76.8% QoQ | 261 139.4% YoY 18.1% QoQ | 168 38.8% YoY -35.6% QoQ | 146 16.8% YoY -13.1% QoQ |
| 2023 | 302 36.7% YoY 106.8% QoQ | 288 10.3% YoY -4.6% QoQ | 257 53.0% YoY -10.8% QoQ | 460 215.1% YoY 79.0% QoQ |
| 2024 | 47 -84.4% YoY -89.8% QoQ | - | - | - |
The average 5 years interest of frontotemporal dementia treatment was 13.36 per week. The last year interest of frontotemporal dementia treatment compared to the last 5 years has changed by 79.49%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 104.43%.
After 39 days of this quarter the interest is at 90.0. Based on that we can calculate that during remaining 52 days it will total up to 210.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 234 | 58 -75.2% QoQ | 54 -6.9% QoQ | 230 325.9% QoQ |
| 2020 | 150 -35.9% YoY -34.8% QoQ | 112 93.1% YoY -25.3% QoQ | 75 38.9% YoY -33.0% QoQ | 60 -73.9% YoY -20.0% QoQ |
| 2021 | 71 -52.7% YoY 18.3% QoQ | 353 215.2% YoY 397.2% QoQ | 25 -66.7% YoY -92.9% QoQ | 159 165.0% YoY 536.0% QoQ |
| 2022 | 204 187.3% YoY 28.3% QoQ | 102 -71.1% YoY -50.0% QoQ | 123 392.0% YoY 20.6% QoQ | 116 -27.0% YoY -5.7% QoQ |
| 2023 | 247 21.1% YoY 112.9% QoQ | 301 195.1% YoY 21.9% QoQ | 110 -10.6% YoY -63.5% QoQ | 154 32.8% YoY 40.0% QoQ |
| 2024 | 90 -63.6% YoY -41.6% QoQ | - | - | - |
The average 5 years interest of Huntington's disease treatment was 11.6 per week. The last year interest of Huntington's disease treatment compared to the last 5 years has changed by 32.59%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 38.81%.
After 34 days of this quarter the interest is at 67.0. Based on that we can calculate that during remaining 58 days it will total up to 181.0. Duchenne muscular dystrophy treatment expected interest is significantly lower compared to same quarter last year (-45.2%) but similar to previous quarter.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2018 | - | - | - | 283 |
| 2019 | 564 99.3% QoQ | 347 -38.5% QoQ | 256 -26.2% QoQ | 398 40.6% YoY 55.5% QoQ |
| 2020 | 295 -47.7% YoY -25.9% QoQ | 181 -47.8% YoY -38.6% QoQ | 212 -17.2% YoY 17.1% QoQ | 193 -51.5% YoY -9.0% QoQ |
| 2021 | 223 -24.4% YoY 15.5% QoQ | 191 5.5% YoY -14.3% QoQ | 155 -26.9% YoY -18.8% QoQ | 158 -18.1% YoY 1.9% QoQ |
| 2022 | 211 -5.4% YoY 33.5% QoQ | 288 50.8% YoY 36.5% QoQ | 62 -60.0% YoY -78.5% QoQ | 330 108.9% YoY 432.3% QoQ |
| 2023 | 278 31.8% YoY -15.8% QoQ | 267 -7.3% YoY -4.0% QoQ | 255 311.3% YoY -4.5% QoQ | 67 -79.7% YoY -73.7% QoQ |
The average 5 years interest of Duchenne muscular dystrophy treatment was 19.98 per week. The last year interest of Duchenne muscular dystrophy treatment compared to the last 5 years has changed by 6.96%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -29.12%.
After 39 days of this quarter the interest is at 71.0. Based on that we can calculate that during remaining 52 days it will total up to 166.0. Alpha-1 antitrypsin deficiency treatment expected interest is significantly higher compared to previous quarter (+95.3%) but similar to same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 76 | 87 14.5% QoQ | 94 8.0% QoQ | 123 30.9% QoQ |
| 2020 | 127 67.1% YoY 3.3% QoQ | 126 44.8% YoY -0.8% QoQ | 284 202.1% YoY 125.4% QoQ | 236 91.9% YoY -16.9% QoQ |
| 2021 | 204 60.6% YoY -13.6% QoQ | 157 24.6% YoY -23.0% QoQ | 193 -32.0% YoY 22.9% QoQ | 80 -66.1% YoY -58.5% QoQ |
| 2022 | 224 9.8% YoY 180.0% QoQ | 79 -49.7% YoY -64.7% QoQ | 207 7.3% YoY 162.0% QoQ | 168 110.0% YoY -18.8% QoQ |
| 2023 | 214 -4.5% YoY 27.4% QoQ | 103 30.4% YoY -51.9% QoQ | 22 -89.4% YoY -78.6% QoQ | 85 -49.4% YoY 286.4% QoQ |
| 2024 | 71 -66.8% YoY -16.5% QoQ | - | - | - |
The average 5 years interest of Alpha-1 antitrypsin deficiency treatment was 11.34 per week. The last year interest of Alpha-1 antitrypsin deficiency treatment compared to the last 5 years has changed by -41.98%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -24.8%.
There is not enough data for spinocerebellar ataxia 3 treatment to provide analysis
There is not enough data for spinocerebellar ataxia 3 treatment to provide correlation calculation
There is not enough data for spinocerebellar ataxia 3 treatment to provide analysis
There is not enough data for CNS disorders treatment (Alzheimer's and Parkinson's diseases) to provide analysis
There is not enough data for CNS disorders treatment (Alzheimer's and Parkinson's diseases) to provide correlation calculation
There is not enough data for CNS disorders treatment (Alzheimer's and Parkinson's diseases) to provide analysis